Image: Packaging of seized GLP-1/GIP products during SAHPRA’s investigation into alleged unlawful manufacturing and distribution practices.
The South African Health Products Regulatory Authority (SAHPRA), together with the South African Pharmacy Council (SAPC), has intensified action against the unlawful manufacturing and distribution of unregistered weight-loss medicines containing semaglutide and tirzepatide.
The action follows a joint inspection conducted on 11 May 2026 at Sentra Pharmacy in Silverton, Pretoria, where authorities seized injectable GLP-1 and GIP products found on site.
Image: Seized injectable GLP-1/GIP product
GLP-1 and GIP medicines are prescription injections designed to help regulate appetite and blood sugar, but health authorities have warned that illegally manufactured versions marketed for weight loss may pose serious health risks.
According to SAHPRA, the investigation revealed that medicines were allegedly being produced and supplied under the pretext of “compounding”, but outside the legal limits permitted in South Africa. Compounding is intended for preparing medication for individual patients with valid prescriptions and cannot be used for large-scale manufacturing or commercial distribution.
Authorities also reported serious concerns regarding product quality and safety, including alleged illegal importation of active ingredients, inadequate sterile conditions, possible contamination risks and the absence of systems to monitor adverse drug reactions.
SAHPRA said some adverse incidents, including hospitalisations, have reportedly been linked to the use of these products.
Image: Boxes of confiscated items during SAHPRA’s investigation into alleged unlawful manufacturing practices.
Authorities also reported serious concerns regarding product quality and safety, including alleged illegal importation of active ingredients, inadequate sterile conditions, possible contamination risks and the absence of systems to monitor adverse drug reactions.
SAHPRA said some adverse incidents, including hospitalisations, have reportedly been linked to the use of these products.
As part of the enforcement action, affected products were seized and the company has been instructed to initiate a full recall of distributed products.
SAHPRA CEO Dr Boitumelo Semete-Makokotlela said unlawful manufacturing and distribution of unregistered medicines poses a serious risk to public health and warned that further regulatory action will be taken where needed.
Members of the public are encouraged to consult healthcare professionals regarding weight management or diabetes treatment options and to report suspicious products or adverse reactions to SAHPRA.
Image credit: South African Health Products Regulatory Authority (SAHPRA)